The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo

McSheehy, PMJ; Forster-Gross, N; El Shemerly, M; Bachmann, F; Roceri, M; Hermann, N; Spickermann, J; Kellenberger, L; Lane, HA

McSheehy, PMJ (通讯作者)，Basilea Pharmaceut Int Ltd, Hegenheimermattweg 167b, CH-4123 Allschwil, Switzerland.

ANTI-CANCER DRUGS, 2023; 34 (4): 532

Abstract

Derazantinib (DZB) is an inhibitor of fibroblast growth factor receptors 1-3 (FGFR1-3), with additional activity against colony-stimulating-factor-1 r......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索